Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Pfizer Inc. is conducting a study titled ‘ATGAM Intravenous Infusion 250mg General Investigation’ to confirm the safety of ATGAM in patients with moderate to severe aplastic anemia in Japan. The study aims to ensure the drug’s safety under actual use conditions, which is crucial for patient safety and regulatory compliance.
Intervention/Treatment: The study tests the drug Anti-human thymocyte immunoglobulin, equine, commonly known as ATGAM. It’s administered intravenously to patients with moderate to severe aplastic anemia, aiming to improve their condition by modulating immune response.
Study Design: This is an observational cohort study with a prospective time perspective. It involves monitoring patients over a 24-week period to gather data on the safety of ATGAM in real-world settings.
Study Timeline: The study began on February 21, 2024, with a primary completion date yet to be announced. The last update was submitted on July 8, 2025, indicating ongoing data collection and analysis.
Market Implications: This study’s progress could influence Pfizer’s stock performance by potentially expanding ATGAM’s market approval and use, especially in Japan. Positive results may enhance investor confidence, while also impacting competitors in the aplastic anemia treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.